Drug Profile
Research programme: oral vaccines - Sublimity Therapeutics
Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Sigmoid Pharma
- Developer Sublimity Therapeutics
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Helicobacter infections; Traveller's diarrhoea
Most Recent Events
- 22 Sep 2023 Oral vaccines are still in preclinical trials for Helicobacter infections and Traveller's diarrhoea in Ireland (PO) (Sigmoid Pharma pipeline, September 2023)
- 22 May 2018 Sigmoid Pharma is now called Sublimity Therapeutics
- 14 Oct 2016 Preclinical trials in Helicobacter infections in Ireland (PO) before October 2016 (Sigmoid Pharma pipeline, October 2016)